Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases.
Biomarker
Chronic liver disease
Cirrhosis
Ductal reaction
Keratin
Prognostic
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
12 11 2020
12 11 2020
Historique:
received:
18
02
2020
accepted:
16
09
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
23
2
2021
Statut:
epublish
Résumé
Keratins (Ks) represent tissue-specific proteins. K18 is produced in hepatocytes while K19, the most widely used ductular reaction (DR) marker, is found in cholangiocytes and hepatic progenitor cells. K18-based serum fragments are commonly used liver disease predictors, while K19-based serum fragments detected through CYFRA21-1 are established tumor but not liver disease markers yet. Since DR reflects the severity of the underlying liver disease, we systematically evaluated the usefulness of CYFRA21-1 in different liver disease severities and etiologies. Hepatic expression of ductular keratins (K7/K19/K23) was analyzed in 57 patients with chronic liver disease (cohort i). Serum CYFRA21-1 levels were measured in 333 Austrians with advanced chronic liver disease (ACLD) of various etiologies undergoing hepatic venous pressure gradient (HVPG) measurement (cohort ii), 231 French patients with alcoholic cirrhosis (cohort iii), and 280 hospitalized Germans with decompensated cirrhosis of various etiologies (cohort iv). (i) Hepatic K19 levels were comparable among F0-F3 fibrosis stages, but increased in cirrhosis. Hepatic K19 mRNA strongly correlated with the levels of other DR-specific keratins. (ii) In ACLD, increased serum CYFRA21-1 associated with the presence of clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg) (OR = 5.87 [2.95-11.68]) and mortality (HR = 3.02 [1.78-5.13]; median follow-up 22 months). (iii) In alcoholic cirrhosis, elevated serum CYFRA21-1 indicated increased risk of death/liver transplantation (HR = 2.59 [1.64-4.09]) and of HCC (HR = 1.74 [1.02-2.96]) over the long term (median follow-up 73 months). (iv) In decompensated cirrhosis, higher serum CYFRA21-1 predicted 90-day mortality (HR = 2.97 [1.92-4.60]) with a moderate accuracy (AUROC 0.64), independently from established prognostic scores. Hepatic K19 mRNA and serum CYFRA21-1 levels rise in cirrhosis. Increased CYFRA21-1 levels associate with the presence of CSPH and reliably indicate mortality in the short and long term independently of conventional liver biochemistry markers or scoring systems. Hence, the widely available serum CYFRA21-1 constitutes a novel, DR-related marker with prognostic implications in patients with different settings of advanced liver disease.
Sections du résumé
BACKGROUND
Keratins (Ks) represent tissue-specific proteins. K18 is produced in hepatocytes while K19, the most widely used ductular reaction (DR) marker, is found in cholangiocytes and hepatic progenitor cells. K18-based serum fragments are commonly used liver disease predictors, while K19-based serum fragments detected through CYFRA21-1 are established tumor but not liver disease markers yet. Since DR reflects the severity of the underlying liver disease, we systematically evaluated the usefulness of CYFRA21-1 in different liver disease severities and etiologies.
METHODS
Hepatic expression of ductular keratins (K7/K19/K23) was analyzed in 57 patients with chronic liver disease (cohort i). Serum CYFRA21-1 levels were measured in 333 Austrians with advanced chronic liver disease (ACLD) of various etiologies undergoing hepatic venous pressure gradient (HVPG) measurement (cohort ii), 231 French patients with alcoholic cirrhosis (cohort iii), and 280 hospitalized Germans with decompensated cirrhosis of various etiologies (cohort iv).
RESULTS
(i) Hepatic K19 levels were comparable among F0-F3 fibrosis stages, but increased in cirrhosis. Hepatic K19 mRNA strongly correlated with the levels of other DR-specific keratins. (ii) In ACLD, increased serum CYFRA21-1 associated with the presence of clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg) (OR = 5.87 [2.95-11.68]) and mortality (HR = 3.02 [1.78-5.13]; median follow-up 22 months). (iii) In alcoholic cirrhosis, elevated serum CYFRA21-1 indicated increased risk of death/liver transplantation (HR = 2.59 [1.64-4.09]) and of HCC (HR = 1.74 [1.02-2.96]) over the long term (median follow-up 73 months). (iv) In decompensated cirrhosis, higher serum CYFRA21-1 predicted 90-day mortality (HR = 2.97 [1.92-4.60]) with a moderate accuracy (AUROC 0.64), independently from established prognostic scores.
CONCLUSIONS
Hepatic K19 mRNA and serum CYFRA21-1 levels rise in cirrhosis. Increased CYFRA21-1 levels associate with the presence of CSPH and reliably indicate mortality in the short and long term independently of conventional liver biochemistry markers or scoring systems. Hence, the widely available serum CYFRA21-1 constitutes a novel, DR-related marker with prognostic implications in patients with different settings of advanced liver disease.
Identifiants
pubmed: 33176798
doi: 10.1186/s12916-020-01784-7
pii: 10.1186/s12916-020-01784-7
pmc: PMC7661160
doi:
Substances chimiques
Biomarkers
0
KRT19 protein, human
0
Keratin-19
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
336Subventions
Organisme : German Research Foundation
ID : STR 1095/4-2
Pays : International
Organisme : German Research Foundation
ID : MU 1373/9-1
Pays : International
Organisme : German Research Foundation
ID : BR 4182/3-1
Pays : International
Références
Br J Cancer. 2017 Apr 11;116(8):1037-1045
pubmed: 28278517
JAMA Oncol. 2018 Oct 1;4(10):e182078
pubmed: 30003238
Hepatology. 2013 Feb;57(2):700-7
pubmed: 22911653
Hepatology. 2018 Oct;68(4):1534-1548
pubmed: 29637581
Clin Gastroenterol Hepatol. 2010 Mar;8(3):289-96, 296.e1-8
pubmed: 19913638
Histochem Cell Biol. 2018 Oct;150(4):351-359
pubmed: 30039330
Clin Sci (Lond). 2015 Nov;129(10):875-83
pubmed: 26201095
Histochem Cell Biol. 2008 Jun;129(6):705-33
pubmed: 18461349
Gastroenterology. 2010 Jul;139(1):335-43.e2
pubmed: 20399781
Hepatology. 2011 Nov;54(5):1707-17
pubmed: 22045674
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
J Cell Sci. 2012 Sep 1;125(Pt 17):3923-8
pubmed: 23104737
Gut. 2014 Apr;63(4):674-85
pubmed: 23958557
J Hepatol. 2018 Feb;68(2):305-315
pubmed: 29154965
Liver Int. 2015 Apr;35(4):1203-12
pubmed: 24930437
Hepatology. 2017 Dec;66(6):1934-1951
pubmed: 28714104
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):
pubmed: 29610398
Gastroenterology. 2014 Feb;146(2):349-56
pubmed: 24315991
Hepatology. 2012 Jun;55(6):1931-41
pubmed: 22278680
Curr Opin Cell Biol. 2015 Feb;32:73-81
pubmed: 25599598
Hepatology. 2016 Sep;64(3):966-76
pubmed: 26853542
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1262-1269
pubmed: 28648950
Am J Pathol. 2018 Jun;188(6):1316-1327
pubmed: 29673755
J Hepatol. 2015 Oct;63(4):962-70
pubmed: 26070409
BMC Cancer. 2015 May 10;15:386
pubmed: 25956656